BRIDGEBIO PHARMA INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2027 and until their successors are duly elected and qualified: Andrew W. Lo, Ph.D.

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Andrew W. Lo, Ph.D.”): 126,242,281 for, 30,581,800 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 86 asset managers below reported 39,661,681 for, 8,916,531 withheld, 970,161 abstained.

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

Description as filed by funds: To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2027 and until their successors are duly elected and qualified: Charles Homcy, M.D.

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Charles Homcy, M.D.”): 145,872,389 for, 10,951,692 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 86 asset managers below reported 44,160,220 for, 140,225 against, 4,798,820 withheld, 449,108 abstained.

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

Description as filed by funds: To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2027 and until their successors are duly elected and qualified: Douglas A. Dachille

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Douglas A. Dachille”): 128,916,085 for, 27,907,996 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 86 asset managers below reported 41,597,771 for, 6,980,441 withheld, 970,161 abstained.

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

Description as filed by funds: To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2027 and until their successors are duly elected and qualified: Neil Kumar, Ph.D.

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Neil Kumar, Ph.D.”): 154,328,316 for, 2,495,765 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 86 asset managers below reported 48,560,719 for, 140,225 against, 398,321 withheld, 449,108 abstained.

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

Description as filed by funds: To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2027 and until their successors are duly elected and qualified: Ronald J. Daniels

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Ronald J. Daniels”): 151,032,065 for, 5,792,016 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 86 asset managers below reported 46,779,574 for, 2,319,691 withheld, 449,108 abstained.

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

Description as filed by funds: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to include an officer exculpation provision that limits the liability of certain of our officers as permitted under current Delaware law.

BRIDGEBIO PHARMA INC.’s own tally for this item (“5. Approval of an Amendment of the Company's Amended and Restated Certificate of Incorporation to include an officer exculpation provision that limits the liability of certain of its officers as permitted under current D”): 151,194,026 for, 5,574,758 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the Officer Exculpation Amendment to the Company's Amended and Restated Certificate of Incorporation to include an officer exculpation provision that limits the liability of certain of its officers as permitted under current Delaware law.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 88 asset managers below reported 48,631,900 for, 827,758 against, 140,225 withheld, 26,311 abstained.

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

Description as filed by funds: To approve the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals.

BRIDGEBIO PHARMA INC.’s own tally for this item (“6. Approval of the Adjournment of the Annual Meeting to the Extent There are Insufficient Votes at the Annual Meeting to Approve Any of the Above Proposals”): 131,826,931 for, 41,878,620 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 6 –Approval of the Adjournment of the Annual Meeting to the Extent There are Insufficient Votes at the Annual Meeting to Approve Any of the Above Proposals The Company's stockholders approved the adjournment of the Annual meeting to the extent that there were insufficient votes at the Annu…”
Support: 76% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 86 asset managers below reported 34,471,910 for, 14,898,027 against, 99,811 abstained.

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

Description as filed by funds: To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 5,000,000 shares.

BRIDGEBIO PHARMA INC.’s own tally for this item (“4. Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan”): 128,958,695 for, 26,656,756 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 - Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan The Company's stockholders approved the amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (th…”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 92 asset managers below reported 39,674,641 for, 9,593,388 against, 140,225 withheld, 238,617 abstained.

Showing the 25 largest of 92 asset managers. See all 92 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

BRIDGEBIO PHARMA INC.’s own tally for this item (“2. Non-binding Advisory Vote on Compensation of Named Executive Officers”): 117,646,141 for, 37,945,949 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 76% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 87 managers: 32,772,839 for, 16,470,266 against, 238,617 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 256 managers: 65,105,025 for, 31,726,384 against, 140,225 withheld, 15,765 abstained, 6,260 not voted, 182,715 mixed. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.

BRIDGEBIO PHARMA INC.’s own tally for this item (“3. Ratification of Appointment of Independent Registered Accounting Firm”): 173,767,607 for, 56,401 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 87 asset managers below reported 49,443,511 for, 0 against, 26,311 abstained.

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.